469 results about "Chronic renal failure" patented technology

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.

An artificial liver system for treating liver failure includes a reservoir to provide albumin-containing dialysis fluid to the patient's peritoneum, an implantable device including a pump to pump the fluid from the peritoneum to the bladder via respective catheters, control circuitry, battery and transceiver; a charging and communication system configured to periodically charge the battery and communicate with the implantable device to retrieve data reflective of the patient's health; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable device and charging and communication system. The monitoring and control software allows a treating physician to remotely adjust the volume, time, and frequency with which fluid is pumped from the peritoneal cavity to the bladder based on the data reflective of the patient's health.

Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.

A peritoneal dialysis solution that is biochemically balanced to correct metabolic acidosis associated with chronic renal failure in a more physiological manner. The peritoneal dialysis solution has a physiological pH, e.g., pH of 7.0 to 7.4, and contains bicarbonate at a concentration that is found in normal blood. Additionally, the solution contains carbon dioxide at a partial pressure that is similar to partial pressure of carbon dioxide found in normal blood. The peritoneal dialysis solution also contains a weak acid with a pKa of less than 5.0.

The present invention is use of arctigenin in preparing medicine for preventing and treating chronic kidney failure and kidney fibrosis. The present invention also provides medicine composition with arctigenin as active component for preventing and treating chronic kidney failure and kidney fibrosis. When the medicine composition is applied in preventing and treating chronic kidney failure and kidney fibrosis, the injection has dosage of 30mg-1000 mg, preferably 30-500 mg, and the orally taken dosage is 50-2000 mg, preferably 50-800 mg.

The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and / or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP / BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.

A method and apparatus for treatment of chronic renal failure by reducing renal perfusion pressure. Treatment is performed by partial occlusion of renal artery. A device to constrict the renal artery may be implanted in the body of a patient and include a renal pressure sensor and a mechanical control applied the renal artery to adjustably constrict a cross sectional area of the artery.

The invention provides a method for determining a dose and dosing schedule, and making dose adjustments of patients taking PBA prodrugs as nitrogen scavengers to treat nitrogen retention states, including ammonia accumulation disorders as well as chronic renal failure, by measuring urinary excretion of phenylacetylglutamine and / or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered waste nitrogen scavenging drug, and to monitoring patients receiving such drugs.

The invention discloses a traditional Chinese medicine for treating chronic renal failure and aims at solving the problems that the prior art supports the life by dialysis so as to result in short life cycle of patients and high cost and the like. The traditional Chinese medicine comprises the following raw materials: 30g of raidx astragali, 10g of white ginseng, 20g of rhizoma atractylodis macrocephalae, 20g of honey-fried licorice root, 20g of poria, 10g of Chinese angelica, 20g of rehmannia glutinosa, 20g of white paeony root, 10g of wrinkled gianthyssop herb, 15g of pinellia tuber and the like. The prescription is used for treating chronic uremia, can invigorate vigour, strengthening the spleen, replenishing blood, nourishing the blood, excreting water, expel toxin, strengthening the kidney and expel toxin, can reduce dialysis gradually by combining the modern medical method, finally separate the dialysis and transfusion, relieve economic burden of the patients, improve disease process fundamentally, improve life quality and courage and prolong life cycle.

The present invention provides a polysulfone type hollow fiber membrane which is reliable in safety and stability of performance and is easily incorporated into a module, and thus can be suitably used in a highly water permeable blood purifier for use in a therapy of chronic renal failure. The present invention relates to a polysulfone type selectively permeable hollow fiber membrane comprising a polysulfone type resin and a hydrophilic polymer as main components, and characterized in that (A) the content of the hydrophilic polymer in the uppermost layer of a surface of the polysulfone type hollow fiber membrane on the blood-contacting side is at least 1.1 times larger than the content of the hydrophilic polymer in the proximate layer of the surface on the blood-contacting side, and (B) the content of the hydrophilic polymer in the uppermost layer of the other surface of the polysulfone type hollow fiber membrane, i.e., the reverse side of the surface on the blood-contacting side, is at least 1.1 times larger than the content of the hydrophilic polymer in the uppermost layer of the surface on the blood-contacting side.

The present invention discloses an alginic acid and / or its salts with low molecular weight, wherein the weight average molecular weight of the alginic acid is from about 700 to about 4500 Daltons, and the molar ratio of guluronic acid to mannuronic acid in the alginic acid is from about 0.6 to about 19. The present invention also discloses the preparative method of making the alginic acid and / or its salts thereof, and the use of them for treating hypertension, chronic renal failure and postprandial hyperglycemia induced by glycosidase. The present invention further discloses pharmaceutical compositions and foods containing the alginic acid with low molecular weight and / or salts thereof as active component.

The invention discloses a novel traditional Chinese medicine composition for treating the symptoms of renal calculus and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw materials of medicines: scaly anteater, rhizoma sparganii, rhizoma zedoariae, sweetgum fruit, immature bitter orange, Chinese eaglewood, dalbergia wood, tangerine peel, TurmericRoot-tuber, chicken's gizzard-membrane, radix notoginseng, rhizoma ligustici wallichii, red peony root, peach kernel, safflower, logwood, mastic, myrrh, draconis sanguis, Chinese polyphaga, rhizoma cyperi, tuckahoe, radix puerariae, rhizoma alismatis, manchurian dutchmanspipe, japanese fern spore, semen lepidii, talcum, rosa banksiae, green tangerine peel, toosendan fruit, areca peel, dahurian angelica root, rhizoma atractylodis, schisandra fruit and motherwort. The traditional Chinese medicine composition can be prepared into any common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can obviously improve the symptoms of the metabolic balance maladjustment of colloids and crystals, infection, nutrition metabolic disturbance, the calculus and the urine stasis of the urinary system, lumbago, renal colic, bloody urine and the like in the body of a patient with the symptoms of the renal calculus, can improve the symptoms of gout, diabetes, hypertension, acute pyelonephritis, chronic renal failure, uremia and the like caused by the symptoms of the renal calculus and has definite clinical curative effect, obvious curative effect and quick acting. Because of basically adopting medicine-food homologous medicines specified by the dispensatory of China for combination, the traditional Chinese medicine composition has the advantages of low cost, no toxic or side effect basically and the like.

The present invention provides polysulfone-based hollow fiber membranes having high water permeable performance and for use in therapy of chronic renal failures, said hollow fiber membranes having high safety and high stability in performance and being excellent in module-fabricating workability. The present invention also provides a process for manufacturing the same. The present invention relates to a bundle of a plurality of selectively permeable polysulfone-based hollow fiber membranes wherein the amount of a hydrophilic polymer eluting from each hollow fiber membrane is not larger than 10 ppm, and wherein the content of the hydrophilic polymer in the outer surface of the hollow fiber membrane is 25 to 50 mass %, and this bundle is characterized in that any of extracted solutions from ten fractions of said bundle, obtained by dividing the bundle at substantially regular intervals along the lengthwise direction, shows a maximum value of smaller than 0.10 in UV absorbance at a wavelength of 220 to 350 nm, with the proviso that the extracted solutions are obtained by the extraction method for tests regulated in the approval manufacturing standards for dialytic artificial kidney devices; and in that the difference between the maximum and the minimum out of the maximum values of UV absorbance of the extracted solutions from the respective fractions is not larger than 0.05.

The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof, which drug is useful not only for amelioration of renal function, but also for amelioration of anemia, activation of SOD and excretion of uremic substances.

The invention relates to a drug preparation and a preparation method thereof, in particular to a compound Alpha-ketonic acid chewable tablet used for curing chronic renal failure, and a preparation method thereof. The compound Alpha-ketonic acid chewable tablet comprises the following components: Alpha-ketophenylalanine calcium, Alpha-hydroxymethionine calcium, Alpha-ketoleucine calcium, Alpha-ketoisoleucine calcium, Alpha-ketovaline calcium, tryptophan, histidine, tyrosine, threonine, lysine, acetate, a filling agent, a bonding agent, a taste-masking agent, a lubricant and a coating agent. The compound Alpha-ketonic acid chewable tablet not only widens the dosage form range of the compound Alpha-ketonic acid chewable tablets, but also has the advantages of having good dispersing state, short disintegration time, fast drug dissolution, rapid absorption, high biological availability and convenient taking, being capable of being swallowed, chewed and sucked and being especially suitable for old people, stroke patients, patients with special diseases and patients having swallowing difficulty.

The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising a phosphate binder and another pharmaceutically active ingredient. The other pharmaceutically active ingredient is selected from a group consisting of antihypertensives, calcitrol, vitamin D analogues, lipid restriction products, potassium salts, treatments for anemia and alkalization compounds.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein / bone morphogenetic protein (OP / BMP) family within the TGF-β superfamily of proteins.

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and / or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and / or treatment of both acute and chronic renal failure in mammals, advantageously in humans, dogs and cats, by intra-vascular kidney administration of the recombinant vectors and pharmaceutical compositions of the invention.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The present invention provides a highly water permeable hollow fiber membrane type blood purifier for medical use, which is excellent in safety and module-assembling ease and which has a high water permeability suitable for use in therapy of chronic renal failure. The present invention relates to a highly water-permeable hollow fiber type blood purifier comprising hydrophobic polymer hollow fiber membranes each of which contains a hydrophilic polymer, characterized in that the amount of the hydrophilic polymer eluted from the hollow fiber membrane is 10 ppm or less; in that the ratio of the hydrophilic polymer in the outer surface of the hollow fiber membrane is 25 to 50 mass %; in that the burst pressure of the hollow fiber membrane is 0.5 MPa or higher; and in that the coefficient of water permeability of the blood purifier is 150 ml / m2 / hr. / mmHg or higher.

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and / or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

An acetic acid- and / or acetate salt-free iron metabolism-improving agent that contains citric acid and / or a citrate salt as electrolytes and also contains another / other electrolyte / electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and / or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and / or the substitution fluid are further provided.

Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided.

The invention provides compositions for preventing chronic feline renal failure comprising from about 28 to about 35% protein and compositions for treating chronic renal failure in felines comprising from about 28 to about 30%, wherein the protein comprises at least about 75% vegetable protein and methods for using such compositions to prevent or treat chronic feline renal failure. The invention also provides methods for preparing the compositions, articles of manufacture comprising the compositions, and means for communicating information about the compositions, methods, and articles of manufacture.

The invention discloses a traditional Chinese medicine composition for treating chronic cardiac failure and a preparation method thereof, applied to the field of traditional Chinese medicines. The traditional Chinese medicine composition comprises traditional Chinese medicine main ingredients and medicinal auxiliary materials, wherein the traditional Chinese medicine main ingredients comprise astragalus, cassia twig, salvia miltiorrhiza, Chinese angelica, ginseng, red flower, motherwort, semen lepidii, poria cocos and pseudo-ginseng; and the medicinal auxiliary materials comprise dextrin, starch and lactose. The preparation method comprises the following steps: heating, refluxing and extracting astragalus, ginseng, pseudo-ginseng, poria cocos, salvia miltiorrhiza and semen lepidii according to a prescription ratio by using ethanol twice, filtering, merging the filtrate, and recovering ethanol to obtain liquid medicine; soaking cassia twig, red flower, motherwort and Chinese angelica according to the prescription ratio, adding the obtained medicine residue, decocting by using water, filtering to obtain liquid medicine, decocting by using water, filtering to obtain liquid medicine, and collecting distillate twice to obtain the liquid medicine; performing spray drying on the concentrated solution, and preparing extract powder; and adding the extract powder into dextrin, uniformly mixing, wetting the granules by using ethanol to obtain a finished preparation. By adopting the method for tonifying qi, promoting blood circulation to remove blood stasis and warming yang to promote diuresis, the clinical symptoms of heart failure patients are improved, the myocardial contractility can be improved, and the pumped blood of venous return is increased, so that the heartbeat is increased, and the myocardial infarction range is narrowed.